CSL Shares Tumble as Phase 3 Trial for Heart Attack Drug Fails
Shares of Australian pharmaceutical giant CSL Ltd (ASX:) dropped 4.5% on Monday after the company announced that a phase 3 trial for its drug, CSL112, failed to meet its primary efficacy endpoint. The trial aimed to determine the drug’s effectiveness in reducing “major adverse cardiovascular events” during the 90-day, high-risk period following an initial heart attack.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
